Distance-Based Exercise to Preserve Function and Prevent Disability

Part of paid clinical trials in Dublin, California.

Sponsor
Alliance for Clinical Trials in Oncology
Study ID
NCT07059884
Status
Recruiting

Conditions

  • Hematopoietic and Lymphatic System Neoplasm
  • Localized Malignant Solid Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Exercise intervention — OTHER
    Complete supervised TH progressive resistance exercise sessions
  • Telemedicine — OTHER
    Complete supervised TH progressive resistance exercise sessions
  • Aerobic Exercise Intervention — OTHER
    Complete unsupervised aerobic exercise sessions
  • Dumbbell Exercise Intervention — OTHER
    Receive adjustable-weight dumbbells
  • Accelerometry — PROCEDURE
    Wear accelerometer
  • Questionnaire Administration — OTHER
    Ancillary studies
  • Interview — OTHER
    Ancillary studies
  • Electronic Health Record Review — OTHER
    Ancillary studies

Study Details

This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.

Key Dates

Start date
Feb 11, 2026
Status verified
Apr 2026
Primary completion
Jan 1, 2027
Completion
Feb 18, 2027

Study Design

Enrollment
104 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Supportive care (DEFEND)
    Patients complete supervised TH exercise sessions consisting of progressive resistance exercise BIW and complete unsupervised aerobic exercise sessions over 30 minutes TIW until the end of SOC chemotherapy or up to a total of 6 months, whichever comes first, in the absence of disease progression or unacceptable toxicity. Patients also receive adjustable-weight dumbbells on study and wear an accelerometer throughout the study.

Primary Outcome Measure

Percentage of completed exercise sessions (Feasibility) [ Time Frame: Up to 6 months ]

Central Contacts

Locations (17)

FacilityCityStateZIPSite coordinators
Kaiser Permanente DublinDublinCalifornia94568
Site Public Contact
877-642-4691
Jennifer M. Suga (PRINCIPAL_INVESTIGATOR)
Kaiser Permanente-FremontFremontCalifornia94538
Site Public Contact
877-642-4691
Jennifer M. Suga (PRINCIPAL_INVESTIGATOR)
Kaiser Permanente Fresno Orchard PlazaFresnoCalifornia93720
Site Public Contact
833-574-2273
Jennifer M. Suga (PRINCIPAL_INVESTIGATOR)
Kaiser Permanente-ModestoModestoCalifornia95356
Site Public Contact
877-642-4691
Jennifer M. Suga (PRINCIPAL_INVESTIGATOR)
Kaiser Permanente-OaklandOaklandCalifornia94611
Site Public Contact
877-642-4691
Jennifer M. Suga (PRINCIPAL_INVESTIGATOR)
Kaiser Permanente-South SacramentoSacramentoCalifornia95823
Site Public Contact
877-642-4691
Jennifer M. Suga (PRINCIPAL_INVESTIGATOR)
Kaiser Permanente-Santa Teresa-San JoseSan JoseCalifornia95119
Site Public Contact
877-642-4691
Jennifer M. Suga (PRINCIPAL_INVESTIGATOR)
Kaiser San Rafael-GallinasSan RafaelCalifornia94903
Site Public Contact
877-642-4691
Jennifer M. Suga (PRINCIPAL_INVESTIGATOR)
Kaiser Permanente-VallejoVallejoCalifornia94589
Site Public Contact
877-642-4691
Jennifer M. Suga (PRINCIPAL_INVESTIGATOR)
Dana-Farber Cancer InstituteBostonMassachusetts02215
Site Public Contact
877-442-3324
Jennifer A. Ligibel (PRINCIPAL_INVESTIGATOR)
Novant Health Cancer Institute - KernersvilleKernersvilleNorth Carolina27284
Site Public Contact
336-718-8335
Judith O. Hopkins (PRINCIPAL_INVESTIGATOR)
Novant Health Cancer Institute - Mount AiryMount AiryNorth Carolina27030
Site Public Contact
336-718-8335
Judith O. Hopkins (PRINCIPAL_INVESTIGATOR)
Novant Health Forsyth Medical CenterWinston-SalemNorth Carolina27103
Site Public Contact
336-718-8335
Judith O. Hopkins (PRINCIPAL_INVESTIGATOR)
UPMC Hillman Cancer Center at Butler Health SystemButlerPennsylvania16001
Site Public Contact
412-389-5208
Kathryn Schmitz (PRINCIPAL_INVESTIGATOR)
IRMC Cancer CenterIndianaPennsylvania15701
Site Public Contact
412-389-5208
Kathryn Schmitz (PRINCIPAL_INVESTIGATOR)
UPMC Hillman Cancer Center - New CastleNew CastlePennsylvania16105
Site Public Contact
412-389-5208
Kathryn Schmitz (PRINCIPAL_INVESTIGATOR)
UPMC Cancer Center at UPMC NorthwestSenecaPennsylvania16346
Site Public Contact
814-676-7900
Kathryn Schmitz (PRINCIPAL_INVESTIGATOR)

Find similar trials in Dublin, CA

Related Studies